From the Department of Interventional Neuroradiology-NEURI Brain Vascular Center (J.-B.G., J. Caroff, J. Cortese, C.M., J.V.M., L.C., L.I., V.C., A.O., G.B.D.A., S.G., J.M., LS.), Bicêtre Hospital, Le Kremlin-Bicêtre, France.
Radiology Department (J.-B.G.), Angers University Hospital, Angers, France.
AJNR Am J Neuroradiol. 2021 Jul;42(7):1276-1281. doi: 10.3174/ajnr.A7115. Epub 2021 Apr 29.
The Woven EndoBridge has proved to be a safe and effective treatment, especially for wide-neck intracranial aneurysms. The recent fifth-generation Woven EndoBridge came with smaller devices. The purpose of this study was to assess the safety and efficiency of Woven EndoBridge treatment of small and very small aneurysms.
Between September 2017 and March 2020, all consecutive patients treated with a 3- or 3.5 mm-width Woven EndoBridge device were included in this retrospective intention-to-treat study. Clinical and radiologic findings were evaluated at immediate and last-available follow-up. Angiographic outcome was assessed by an external expert reader.
One hundred twenty-eight aneurysms were treated with a fifth-generation Woven EndoBridge device including 29 with a width of ≤3.5 mm. Ten aneurysms were ruptured (34%). In 3 cases (10%), Woven EndoBridge treatment could not be performed because the aneurysm was still too small for the smallest available Woven EndoBridge device and another endovascular strategy was chosen. The median follow-up time was 11.2 months. Complete and adequate occlusion was obtained in 71% and 90% of the treated aneurysms, respectively. Retreatment was needed in 2 cases (10%). Symptomatic ischemic complications leading to transient neurologic deficits occurred in 2 cases (7%) (1 procedure-related and 1 device-related) but with full spontaneous recovery at discharge.
The fifth-generation Woven EndoBridge device seems to be a safe and technically feasible treatment for both ruptured and unruptured small and very small intracranial aneurysms, with satisfactory occlusion rates on midterm follow-up. However, further study is needed to evaluate longer-term efficiency.
编织型 EndoBridge 已被证明是一种安全有效的治疗方法,尤其适用于宽颈颅内动脉瘤。最近推出的第五代编织型 EndoBridge 具有更小的器械。本研究旨在评估编织型 EndoBridge 治疗小和非常小动脉瘤的安全性和有效性。
在 2017 年 9 月至 2020 年 3 月期间,所有连续接受 3 或 3.5mm 宽度编织型 EndoBridge 装置治疗的患者均被纳入本回顾性意向治疗研究。在即时和最后一次随访时评估临床和放射学发现。由外部专家读者评估血管造影结果。
128 个动脉瘤接受了第五代编织型 EndoBridge 装置治疗,其中 29 个动脉瘤的宽度≤3.5mm。10 个动脉瘤破裂(34%)。在 3 例(10%)中,由于动脉瘤对于最小可用的编织型 EndoBridge 装置仍然太小,无法进行编织型 EndoBridge 治疗,因此选择了另一种血管内治疗策略。中位随访时间为 11.2 个月。分别有 71%和 90%的治疗动脉瘤获得完全和充分闭塞。有 2 例(10%)需要再次治疗。2 例(7%)发生症状性缺血性并发症导致短暂神经功能缺损(1 例与操作相关,1 例与器械相关),但在出院时完全自发恢复。
第五代编织型 EndoBridge 装置似乎是一种安全且技术可行的治疗方法,适用于破裂和未破裂的小和非常小颅内动脉瘤,中期随访闭塞率令人满意。然而,需要进一步研究来评估更长期的效果。